Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients

CompletedOBSERVATIONAL

Enrollment

249

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

August 23, 2023

Study Completion Date

August 23, 2023

Conditions

COVID-19 Respiratory InfectionAspergillosis

Interventions

DRUG

Posaconazole

Intravenous posaconazole prophylaxis

Trial Locations (3)

Medical University of Graz, Graz

San Martino Polyclinic Hospital IRCCS, Genova

University of Rennes, Rennes

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Medical University of Graz

OTHER

NCT05065658 - Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients | Biotech Hunter | Biotech Hunter